Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910876910/en/
(Graphic: Business Wire)
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech's extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech's project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company's ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
Contacts
Media
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip, Nokia and GSMA demonstrate benefits of Network APIs at industry-leading developer conference Shift11.9.2024 10:00:00 CEST | Press release
Global communications platformInfobipis bringing together global mobile telecoms business Nokia, mobile industry association GSMA, leading Croatian telco Croatian Telekom (Hrvatski Telekom) and other companies at its leading developer-focused conference Shift this year. Following several successful partnerships launching Camara-compliant Network APIs under the GSMA Open Gateway initiative, telcos and MNOs globally want to launch and monetize emerging and future services. Many firms still need better relationships with developers to do so quickly and efficiently. That’s why MNOs are attending Infobip Shift this year. Matija Ražem, VP of Business Development, Infobip, said: “We are among the first to support the Camara project and the GSMA Open Gateway initiative, and working with telcos to deliver new added-value services. Our collaboration with Nokia, GSMA, and other MNOs at Shift Zadar shows how we work with telco partners to expose customer experience-friendly APIs to developers.” At
EORTC Extends Medidata Partnership to Help Power New Phase of Oncology Research11.9.2024 09:00:00 CEST | Press release
Medidata technology deployed to increase access to and transform the patient experience for cancer trials Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and the European Organisation for Research and Treatment of Cancer (EORTC), announced today a four-year extension to their partnership. The extended relationship will enable EORTC to further increase patient access to oncology clinical trials, make trial participation easier, and help to deliver new treatments to the market faster. EORTC is now leveraging 13 Medidata solutions, enabling their researchers to access and manage all clinical data in a single place and offering patients a seamless trial experience. Vassilis Golfinopoulos, headquarters director, EORTC, said, “We chose the Medidata Platform to further expand our data management and patient engagement capabilities based on our years of experience working together. This partnership will enhance our support for
Crystal Intelligence Partners with Leading Global Payments Provider, Clear Junction, to Strengthen Transaction Monitoring and Regulatory Controls for Digital Assets11.9.2024 09:00:00 CEST | Press release
The partnership aims to create enhanced regulatory controls and security for institutional clients worldwide Crystal Intelligence, a leader in digital asset compliance and risk management, has partnered with Clear Junction, a global correspondent account service provider, to strengthen regulatory controls and security for its digital asset transactions. Through this partnership, Crystal will integrate its advanced blockchain analytics and compliance technology within Clear Junction’s rigorous risk management framework to further enhance security measures for its institutional clients globally. Dima Kats, CEO of Clear Junction, stated, “We are glad to partner with Crystal, one of the industry leaders in digital asset compliance. At Clear Junction, we are committed to continuously investing in and strengthening our risk management protocols to ensure the utmost security and regulatory compliance of our operations.” Clear Junction is committed to bring its transaction screening protocols
Shin-Etsu Chemical Develops Industry-First Heat-Shrinkable Silicone Rubber Tubing for Busbar Covering11.9.2024 08:00:00 CEST | Press release
Shin-Etsu Chemical Co., Ltd. (TOKYO: 4063) (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed the ST-OR Type heat-shrinkable silicone rubber tubing for busbar covering for the first time in the industry*. A busbar is a conductive metallic strip, typically made of copper or aluminum, and is used for power connection or distribution. Busbars have found wide-ranging applications and grown in demand for use not only in switchboards and control panels but also in electric vehicles (EVs) and hybrid vehicles (HEVs) more recently. For being subjected to high currents and high voltages, busbars are protected with tape, tubing, or other insulating parts. In particular, busbars used in EVs and HEVs must endure even higher voltages and currents and thus require insulating parts that provide more advanced properties, including superior electrical insulation and heat resistance. The ST-OR Type heat-shrinkable silicone rubber tubing for busbar covering, whic
Tula Technology Expands DMD into China, the World’s Electrified Vehicle Market Leader11.9.2024 02:00:00 CEST | Press release
Testing shows 0.6% increased efficiency for Chinese premium full-size SUV with potential for more Tula Technology, Inc., a leader in propulsion efficiency, along with a leading global automotive supplier, has developed a Dynamic Motor Drive® (DMD) demonstration vehicle for the Chinese market based on a domestic premium full-size SUV. DMD is a cost-effective, software-only technology that improves electrified vehicle efficiency and addresses key challenges facing the EV transition: range, battery size, and cost. Tula’s goal with DMD is to aid the switch to electric vehicles by improving their efficiency, and also the efficiency of transitional vehicles like plug-in hybrids. The demonstration vehicle was developed around a plug-in hybrid full-size SUV, specifically a range-extended EV that includes a small internal combustion engine used only for charging the traction battery. Tula’s DMD was implemented onto the rear primary eDrive, which consisted of an Interior Permanent Magnet (IPM) m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom